New Publication: Bulletin MADRAC - April 2016

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Bulletin MADRAC

April 2016

 

  • Welcoming the new MADRAC members (2016-2018)
  • Pharmacogenomics in Determining Drug Response
  • Azithromycin: Risk of QT Prolongation and DRESS
  • Mycophenolate: Important New Information on the Teratogenic Risk
  • Prolia® and Xgeva® (denosumab): Clinically Significant Cases of Hypercalcaemia after Cessation of Treatment with Denosumab in Paediatric Patients
  • Viekirax® and Exviera®: Not Recommended in Patients with Moderate Hepatic Impairment (Child-Pugh B)
  • Xalkori® (crizotinib): Inclusion of a New Warning Regarding Cardiac Failure
  • Pharmacists: CPD Points for Quality ADR Reports

 



 
 
  DOWNLOAD PDF


 

 

 

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA